Advanced Science. Uncovering Risk.
Matching Patients to their optimal treatments through molecular age signatures
Clinicians often use a patient’s age to make treatment decisions in a wide range of clinical scenarios. However, chronological age is an unreliable predictor of individual’s risk posed by surgical procedures and therapeutic interventions. An individual’s rate of aging is strongly influenced by environmental, genetic, and lifestyle factors which are not accounted for by chronological age alone. In contrast, biomarkers of molecular age provide a snapshot of the overall health and resiliency of the body, thus allowing physicians to better know their patients and more accurately predict their health risks.
AKI-SapereTM, is being clinically validated in a cardiovascular disease setting to identify patients at high risk for acute kidney injury, adverse cardiac outcomes, rehospitalization and death.
Expression of p16 aging biomarker is a powerful predictor of patient frailty and is being clinically validated in multiple clincal settings.